EP Biocomposites Board of Directors
Get the latest insights into the leadership at EP Biocomposites. Learn about the experienced professionals guiding the company's strategy and governance.
| Name | Position |
|---|---|
| Mr. Rajkumar Gajanan Kamat | Managing Director |
| Mr. Shreyas Dattatray Nadkarni | Director |
| Ms. Leena Kamat | Director |
| Mr. Nitin Anant Kunkolienker | Independent Director |
| Mr. Dinesh Naguesh Shenoy | Independent Director |
EP Biocomposites Share price
EPBIO
114
14.00 (-10.94%)Last updated on 4 Nov, 2025 | 15:08 IST
BUYSELL
Today's High
115.00
Today's Low
110.00
52 Week Low
98.00
52 Week High
230.50
The current prices are delayed, login to your account for live prices
LoginEP Biocomposites FAQs
The board at EP Biocomposites consists of experienced professionals, including Mr. Rajkumar Gajanan Kamat , Mr. Shreyas Dattatray Nadkarni , and others, overseeing the company’s strategic and corporate governance.
Directors at EP Biocomposites are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.
As of the latest update, Mr. Rajkumar Gajanan Kamat is the current chairman at EP Biocomposites.
Executive directors at EP Biocomposites are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.
Yes, EP Biocomposites adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.
At EP Biocomposites, board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.